Ulo Palm - 07 Mar 2023 Form 4 Insider Report for Vaxxinity, Inc.

Reporting relationship: Chief Medical Officer.
Issuer ticker: N/A
Reported as of: 07 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Apr 2023, 15:59:43 UTC
Prior SEC filing: 15 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Rene Paula Molina as Attorney-in-Fact for Ulo Palm

Key filing fact

Ulo Palm filed Form 4 for Vaxxinity, Inc. on 04 Apr 2023.

Key facts

This page summarizes Ulo Palm's Form 4 filing for Vaxxinity, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Apr 2023, 15:59.

Change

Previous filing in this sequence was filed on 15 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VAXX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +123,418
Change %
Price: $0.000000
Shares after: 123,418
Date: 07 Mar 2023
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 123,418
Exercise price: $2.29
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options were issued to the Reporting Person pursuant to the Issuer's 2021 Omnibus Incentive Compensation Plan. Such options vest in 48 equal monthly installments beginning on March 7, 2023.

SEC remarks

Chief Medical Officer.